natgillin/translations-raw huggingface dataset:
A method of detecting or measuring myostatin in a sample comprising contacting the sample with the polypeptide of any one of embodiments 1-117, and detecting or measuring binding of the polypeptide to myostatin. A polypeptide comprising a fibronectin type III tenth (10Fn3) domain, wherein the polypeptide binds myostatin with a KD of less than 500 nM and the amino acid sequences of the BC, DE and FG loops of the 10Fn3 domain comprise the amino acid sequences of SEQ ID NOs: 34, 39 and 75, respectively, and optionally wherein 
(1) - polipeptid se veže na miostatin s X, manjim od 500 nM; 1 (ii) aminokiselinski sljedovi u petljama BC, DE i FG u domeni '"Fn3 imaju aminokiselinske sljedove u SEQ ID NO: 34, 39 odnosno 75, gdje jedna petlja od petlji BC, DE i FG u domeni '"Fn3 može imati jednu aminokiselinsku zamjenu prema odgovarajućim petljana BC, DE 1 FG u SEQ ID NO: 34, 39 i 75.
FIG. 18 is a view showing another embodiment of the symbol mapper. 
(od podožralog, Pabikovani j GhikO is simbol sjanja i
In the preparation of pharmaceutical compositions in form of emulsions or microemulsions according to the invention herein disclosed, said at least one co-surfactant can be selected in the groups comprising, but not limited to: low and medium chain alcohols, such as ethanol, propanol, isopropanol and the like; glycols, such as propylene glycol and the like; polyethylene glycols, such as PEG 200, PEG 300, PEG 400 and the like; DMSO; long chain alcohols, such as cetyl alcohol, myristyl alcohol, oleyl alcohol and the like; glycerol; low chain esters, such as ethyl acetate, ethyl lactate and the like; fatty acid esters, such as ethyl oleate, isopropyl myristate, isopropyl palmitate and the like; fatty acids, such as oleic acid, myristic acid and the like; salts of fatty acids, such as sodium oleate, sodium palmitate, sodium stearate and the like. 
Farmaceutski pripravak u obliku emulzije ili mikroemulzije prema zahtjevu 1, gdje ta uljna faza sadrži barem jedan lipofilni spoj. Farmaceutski pripravak u obliku emulzije ili mikroemulzije prema zahtjevu 10, gdje se taj barem jedan lipofilni spoj odabire između prirodnih ulja, kao što su bademovo ulje, kanola ulje, ricinusovo ulje, kukuruzno ulje, pamučno ulje, maslinovo ulje, ulje šafranike, sezamovo ulje, sojino ulje; estera masnih kiselina, kao što su izopropil palmitat, izopropil miristat, etil oleat; masnih alkohola, kao što su miristinski alkohol, oleinski alkohol; masnih kiselina, kao što su miristinska kiselina, oleinska kiselina, palmitinska kiselina; triglicerida, kao što su dugolančani i/ili srednjelančani trigliceridi; diglicerida 1 monoglicerida.
According to a further preferred embodiment after sampling a container is provided and the contents of the sampling tube is transferred with a container which is subsequently closed and shipped. 
U skladu s jednim daljnjim povoljnim ostvarenjem nakon uzimanje uzorka osigura se jedan spremnik i sadržaj iz cijevi za uzimanje uzorka se premjesti u taj spremnik koji se nakon toga zatvori i otpremi.
It is also conceivable that the lid comprises an edge wall, wherein the hinge line of the lid is not located at a top wall of the lid, but is arranged at that edge wall. 
HR P20120569 T1 Omot za pakiranje u skladu s patentnim zahtjevom 1, naznačen time što poklopac ima stjenku brida, pri čemu se linija za preklapanje poklopca nalazi na stjenki brida.
The addition of urea involves, however, a considerable complication in the preparatory step, in as much as the urea has to be dissolved in the resin dispersion immediately before use; the dispersion itself must be heated in order to avoid precipitation due to the cooling caused by the urea dissolution and furthermore because there must be provided a control and correction of the pH which may turn out to have changed because of the addition of urea or other blocking agents. 
Dodatak urina prouzrokuje popriličnu komplikaciju u stupnju pripreme, jer treba urin rastopiti u disperziji smole neposredno prije upotrebe; disperziju samu potrebno je zagrijavati, da izbjegnemo taloženje zbog hlađenja, kojeg prouzrokuje rastapanje urina, pored toga potrebno se je pobrinuti za kontrolu i korekciju pH. pH se naime može promijeniti zbog dodatka urina ili drugih sredstava za blokiranje. HR P940799 B1 Opis rješenja tehničkog problema sa izvedbenim primjerima
The PDE1 enzyme inhibitor according to claim 1, wherein R2 of said compound of formula (I) is H or —CH3. 
Spoj sukladno zahtjevu 1, pri čemu R2 je H ili -CH3.
A composition according to claim 1, which comprises as component (A) the compound 3-difluoromethyl-1-methyl-1H-pyrazole-4-carboxylic acid (9-dichloromethylidene-benzonorbornene-5-yl)amide and as component (B) fenpropidin. 
Pripravak prema zahtjevu 1, naznačen time da kao komponentu (A) sadrži spoj 3-difluorometil-1-metil-1Hpirazol-4-karboksilna kiselina (9-diklorometiliden-benzonorbornen-5-iljamid, te kao komponentu (B) fluopiram.
Rb represents an Ra group or a -Y-carbocyclic or -Z-heterocyclyl group wherein said carbocyclic and heterocyclyl groups may be optionally substituted by 1, 2 or 3 Ra groups; 
Rb predstavlja Ra grupu ili -Y-karbocikličku ili -Z-heterociklil grupu, pri čemu spomenute karbocikličke i heterociklil grupe mogu biti po izboru supstituirane s 1, 2 ili 3 Ra grupe;
The method according to claim 1, wherein the hollow bodies (11) are constructed as earth-improvement hollow bodies (11), which have hollow interior spaces in which a carbon-contained substance (113) or an earth-improvement agent is deposited. 
Postupak u skladu s patentnim zahtjevom 1, naznačen time što su šuplja tijela (11) konstruirana kao šuplja tijela za poboljšavanje tla (11), čiji su šuplji unutarnji prostori ispunjeni tvari koja sadrži ugljik (113) ili sredstvom za poboljšavanje tla.
A spontaneously dispersible pharmaceutical composition as claimed in claim 3 wherein the antioxidant is ascorbyl palmitate. 
Spontano disperzibilni farmaceutski pripravak u skladu s patentnim zahtjevom 3, naznačen time što je antioksidans askorbil-palmitat.
A method for making a humanized rodent, comprising replacing a genomic fragment of a rodent IL-4Ra gene at an endogenous rodent IL-4Ra locus with a genomic fragment of a human IL-4Ra gene to form a humanized IL-4Ra gene comprising the ATG initiation codon of coding exon 1 through coding exon 5 of the human IL-4Ra gene, and coding exons 6-9 of the rodent IL-4Ra gene, wherein the genomic fragment of the rodent IL-4Ra gene comprises the ATG initiation codon of coding exon 1 through coding exon 5 of the rodent IL-4Ra gene, and the genomic fragment of the human IL-4Ra gene comprises the ATG initiation gene of coding exon 1 through coding exon 5 of the human IL-4Ra gene, and the humanized IL-4Ra gene is operably linked to rodent IL-4Ra regulatory elements at the endogenous rodent IL-4Ra locus. 
Postupak dobivanja humaniziranog glodavca, naznačen time što se sastoji u zamjeni genomskog fragmenta gena za glodavački IL-4Ra na lokusu za endogeni glodavački IL-4Ra. genomskim fragmentom gena za ljudski IL-4Ra kako bi se dobilo gen za humanizirani IL-4Ra. koji sadrži početni kodon ATG kodirajućeg egzona 1 do kodirajućeg egzona 5 gena za ljudski IL-4Ro, te kodirajuće egzone 6-9 gena za glodavački IL-4Ra, gdje genomski fragment gena za glodavački IL-4Ra. sadrži početni kodon ATG kodirajućeg egzona 1 do kodirajućeg egzona 5 gena za glodavački IL-4Ra, a genomski fragment gena za ljudski IL-4Ra sadrži početni gen ATG kodirajućeg egzona 1 do kodirajućeg egzona 5 gena za ljudski IL-4Ra, gdje je gen za humanizirani IL-4Ro. operativno povezan s regulacijskim elementim glodavačkog IL-4Ra na lokusu za endogeni glodavački IL-4Ra.
a cancer selected from the group consisting of breast cancer, head and neck cancer, lung cancer, ovarian cancer, pancreatic cancer, multiple myeloma, colorectal carcinoma, prostate cancer, renal cell carcinoma, melanoma, hepatocellular carcinoma, cervical cancer, sarcomas, brain tumors, gastric cancers, multiple myeloma, leukemia and lymphomas; 
Kombinacija iz patentnog zahtjeva 1, pri čemu je karcinom odabran iz grupe koja se sastoji od karcinoma dojke, karcinoma glave 1 vrata, karcinoma pluća, karcinoma jajnika, karcinoma gušterače, kolorektalnog karcinoma, karcinoma prostate, karcinoma stanica bubrega, melanoma, hepatocelularnog karcinoma, karcinoma cerviksa, sarkoma, tumora na mozgu, karcinoma želuca, multiplog mijeloma, leukemije i limfoma.
or a pharmaceutically acceptable salt, pharmaceutically acceptable prodrug, or pharmaceutically active metabolite of said compound. 
CN, pri čemu su R? i R" kao što je prethodno definirano; ili farmaceutski prihvatljiva sol navedenog spoja.
is H, halogen, C1-7 alkyl, C1-7 alkoxy, cyano or an optionally substituted 5-6 membered heterocyclic ring; 
Rs je H, halogen, Cr; alkil, C,.; alkoksi, cijano ili po izboru supstituirani petero do šesteročlani heterociklički prsten;
where the compound of formula (I) contains a tertiary amino group, a secondary amino derivative thereof (—-NRaRb→—NHRa or —NHRb); 
la dok nakon toga slijedi reakcija s aminom HN(R?)(R?) za dobivanje spoja formule (I); ili 5
The N-terminal or “extracellular domain of ROBO2”, comprising the five immunoglobulin motifs and three fibronectin type III (FNIII) repeats can be referred to as ROBO2(46-848) of SEQ ID NO: 1 or ROBO2(30-832) of SEQ ID NO: 3, for example. 
3. < Farmaceutski pripravak u skladu s patentnim zahtjevima 1 ili 2, naznačen time što domena koja se veže na Ig1 SLIT sadrži aminokiselinske ostatke 46-145 iz SEQ ID NO: 1 ili aminokiselinske ostatke 30-129 iz SEQ ID NO: 3.
Examples of dosage forms include lozenges which contain sugars and adhesive substances including gums. 
Primjeri oblika doze obuhvaćaju tablete koje sadrže šećere i adhezivne supstance uključujući gume.
the diuretic agent is selected from amiloride, anticholinergics, ipratropium, atropine and oxitropium; or (viii) the hormone or therapeutic peptide or protein is selected from cortisone, hydrocortisone, prednisolone, xanthines, aminophylline, choline theophyllinate, lysine theophyllinate, theophylline, insulin and glucagon; or 
diuretičko sredstvo se bira između amilorida, antikolinergika, ipratropija, atropin i oksitropija; ili (viii) hormon ili terapijski peptid ili protein se bira između kortizona, hidrokortizona, prednizolona, ksantina, aminofilina, kolin-teofilinata, lizin-teofilinata, teofilina, inzulina i glukagona; ili
an elongated mould having an internal surface configured for receiving reinforcing fibres and synthetic resin, said internal surface of the elongated mould having a tapered shape, optionally a frusto-conical one, 
izduljeni kalup (2) koji ima unutarnju površinu (3), konfiguriranu za prihvaćanje ojačavajućih vlakana i sintetske smole, gdje je navedena unutarnja površina (3) izduljenog kalupa (2) sužavajućeg oblika, moguće u obliku krnjeg stošca, -
(0-3) reducing the nitro group of the compound of formula II' to obtain a compound of formula II" or (0-1') providing a compound of formula I' wherein X is Cl or Br, 
(0-3) redukcija nitro-skupine od spoja formule II' u svrhu dobivanja spoja formule II'', ili sljedećih koraka: 5 (0-1) pripravljanje spoja formule I' x
the tetanus antigen in the form of tetanus toxin T, 
- antigen tetanusa u obliku toksina tetanusa T,
The method according to claim 1 wherein the carboxylic acid nucleophile is an cyclic acid containing from four to seven carbon atoms. 
Postupak prema patentnim zahtjevima 1 ili 2 naznačen time da je nukleofil karboksilne kiseline prstenasta kiselina koja sadrži četiri do sedam atoma ugljika.
A compound according to claim 1, or a pharmaceutical composition according to claim 2, for use in the treatment of diseases or disorders associated with uncontrolled, abnormal, and/or unwanted cellular activities. 
[image] ili njegova farmaceutski prihvatljiva sol, pri čemu se on upotrebljava u liječenju bolesti ili poremećaja koja/i je odabran/a od sljedećih: genitalno-urinarni rak, glioblastom, rak tankog crijeva i rak dojke.
For the treatment of HCV infection, the compound of the present invention may also be administered in combination with an agent that is an inhibitor of HCV NS5B polymerase. 
Uporaba spoja prema patentnom zahtjevu 1 ili 2 ili njegove farmaceutski prihvatljive soli u pripremi lijeka za prevenciju ili liječenje HCV infekcije.
Legend of the Figures: 
Broj objave europskog patenta:
A seed comprising one or more exogenous sequences integrated into the Zp15 locus by the method of claim 1 . 
Sjeme, naznačeno time, da obuhvaća jednu ili više egzogenih sekvenci integriranih u Zp1/5-lokus pomoću postupka u skladu sa zahtjevom 1.
In one embodiment the antibody of the invention is coupled to a therapeutic agent such as a toxin, a radioisotope, a drug or a cytotoxic agent. 
Konjugat koji sadrži protutijelo sukladno patentnom zahtjevu 1 spojeno s terapeutskim sredstvom, pri čemu je terapeutsko sredstvo poželjno toksin, radioizotop, lijek ili citotoksično sredstvo.
Amides of the formula VIII can be prepared by coupling of the corresponding 2-mercapto-benzamides (synthesised by reduction of the corresponding 2,2′-dithiobenzamides analogous to those described in e.g. Elworthy, T. R.; Ford, A. P. D. W.; Bantle, G. W.; Morgans, D. J.; Ozer, R. S.; et al. J. Med. 
Amidi formule VII mogu se pripraviti vezanjem odgovarajućih 2- merkapto-benzamida (sintetiziranih redukcijom odgovarajućeg 2,2-ditiobenzamida analogno postupcima opisanim u Elworthy, T.R; Ford, A.P.O.W.; Bantle, G.W.; Morgans, DJ.: Ozer. R.S.: et al. J. Med.
The valve means can comprise a flexible lip arranged to engage in closure the adjacent wall of the capsule and be biased in opening by effect of the pressure so as to disengage from the adjacent wall. 
Kapsula u skladu s patentnim zahtjevom 7, naznačena time što ventil sadrži fleksibilan rub (15), tako podešen da zatvara susjednu stijenku (6) kapsule, te da se otvara pod djelovanjem tlaka na takav način da se odvoji od susjedne stijenke.
Blood is collected in trisodium citrate (3.8%, 1:10). 
Krv je sakupljena u trinatrij citrat (3.8%, 1:10).
The process according to claim 1, in which the supply flow rate is gradually increased in phase b). 
Postupak prema jednom od zahtjeva 1 do 6, naznačen time da se brzina protoka dovoda postupno povećava u fazi b).
The present invention relates to a vaccine comprising at least two fragments of Proprotein convertase subtilisin/kexin type 9 (PCSK9), wherein said at least two fragments comprise at least 8 consecutive amino acid residues of amino acid residues 150 to 170 and/or 205 to 225 of PCSK9 (SEQ ID No. 9). 
HR P20160392 T1 PATENTNI ZAHTJEVI Cjepivo, naznačeno time, da obuhvaća najmanje dva fragmenta proproteinske konvertaze subtilizin/keksin tipa 9 (PCSK9), pri čemu barem jedan od navedena najmanje dva fragmenta sadrže najmanje osam uzastopnih aminokiselinskih ostataka od aminokiselinskih ostataka 150 do 170 od PCSK9 u skladu sa
Tumour volume was assessed twice weekly by bilateral Vernier calliper measurement, using the formula (length x width) x √(length x width) x (π/6), where length was the longest diameter across the tumour, and width was the corresponding perpendicular. 
Volumen tumora računat je dva puta tjedno pomoću pomične mjerke Vernier i formule (duljina x širina) x v (duljna x širina) x (1/6), pri čemu je za duljinu uzet najveći promjer tumora, a širina je bila odgovarajuća duljina okomice.
Cannabinoids work through selective binding to and activation of G-protein coupled cannabinoid receptors. 
Kanabinoidi djeluju kroz selektivno vezanje na i aktivaciju kanabinoid receptora koji su vezani na G-protein.
fish oil, rich in omega-3-acids said composition formulated for transmucosal sublingual, buccal or nasal dosage. 
omega-3-morski trigliceridi; i riblje ulje, bogato u omega-3-kiselinama pri čemu je navedena kompozicija formulirana za transmukozalno sublingvalno, bukalno ili nazalno doziranje.
A pharmaceutical composition according to claim 15, additionally comprising other active ingredients. 
Farmaceutska kompozicija prema patentnom zahtjevu 13, naznačena time da dodatno obuhvaća druge aktivne sastojke.
Furthermore, the transfer surface may be designed to be directly brought into contact with the substrate, which may be a sheet or web. 
Osim toga, površina za prenošenje može biti izrađena tako da izravno dolazi u kontakt s podlogom, koja može biti list papira ili tkanina.
Also within the scope of the invention is the use of any compound of the invention for the manufacture of a medicament for the therapy of anxious depression. 
Uporaba spoja prema zahtjevu 1 ili 2 naznačena time da je za proizvodnju lijeka za liječenje bola.
A compound of general formula (I) according to claim 1 or a pharmaceutically acceptable salt or stereoisomer thereof wherein R, L, X are as defined in claim 1 and Y is a bivalent radical having the following meaning: straight or branched C1-C20 alkylene, being optionally substituted with one or more of the substituents selected from the group consisting of: halogen atoms, hydroxy, -ONO2 or T, wherein T is 
Spoj opće formule (I) prema bilo kojem od patentnih zahtjeva 1 do 2, naznačen time da Y jest dvovalentni radikal koji ima sljedeće značenje: a) - ravni ili razgranati C»-Cg alkilen koji može biti supstituiran s -ONO, ili T, gdje T jest kao što je definirano u patentnom zahtjevu 1, b) CE)
In particular, the cis -dihydrotetrabenazines exhibit both dopaminergic and serotinergic inhibitory actions. 
Točnije, 2R,3R,11bS izomer pokazuje i dopaminergično i serotoninsko inhibirajuće djelovanje.
Coating composition according to claim 1 or 2, characterised in that said SMGCC has a volume median diameter d 50 of between 0.08 and 0.3 µm, preferably of between 0.1 and 0.2 µm, e.g. 0.15 µm. 
Sastav za oblaganje u skladu s patentnim zahtjevom 1 ili 2, karakteriziran na način da navedeni SNGCC ima srednji promjer (d50 (Mal)) između 0.1 i 0.3 µm.
at least one remote energy generation plant which is operated by a renewable energy source, 
* daljinsko postrojenje za stvaranje energije (10), koje iskorištava obnovljivi izvor energije,
The conditional replication defective CMV of embodiment 9, wherein the genome of the CMV is SEQ ID NO:14. 
Citomegalovirus (CMV) s uvjetno defektnom replikacijom sa destabiliziranim IE1/2 i ULSI proteinima, naznačen time što je genom CMV predstavljen sa SEQ ID NO: 14.
The loop regions of Igk-C and Igl-C of murine origin comprise preferably amino acids 8 to 20, amino acids 26 to 36, amino acids 43 to 79, amino acids 83 to 85, amino acids 90 to 101, amino acids 108 to 116 and amino acids 122 to 125. 
Postupak u skladu sa zahtjevom 19 ili 20, naznačen time, da imunoglobulin obuhvaća neko od područja petlje Igkapa ili Ig-lambda koja obuhvaćaju modifikaciju u jednom aminokiselinskom položaju unutar aminokiselinske sekvence izabrane iz skupine koju čine aminokiseline 8 do 20, aminokiseline 26 do 36, aminokiseline 43 do 79, aminokiseline 83 do 85, aminokiseline 90 do 101, aminokiseline 108 do 116 i aminokiseline 122 do 125, pri čemu je numeriranje prema IMGT.
characterized in that the integral key sensing part (206b) of each locking tumbler in said subset comprises at least two neighboring key contacting portions (210a, 211a) in the form of projecting lugs being mutually displaced from each other longitudinally along said key plug axis and being confined within a limited region, at a mutual distance not exceeding ¾ of the distance between the central axes of two adjacent locking tumblers in said row, 
- < integralni dio za raspoznavanje ključa (206b) svakog čepića za zaključavanje u spomenutom podskupu sadrži barem dva susjedna dijela za kontakt s ključem (210a, 211a) u obliku izbočenih stopica koje su međusobno uzdužno pomaknute uzduž navedene osi uloška za ključ i koji su ograničeni unutar ograničenog područja, na međusobnoj udaljenosti koja ne prelazi 3/4 udaljenosti između središnjih osi dvaju susjednih čepića za zaključavanje u navedenom redu,
Compounds of Formula II are commercially available or may be prepared using conventional techniques or analogous processes to those described in the prior art. 
Spojevi prikazani Formulom II su komercijalno dostupni, ili se mogu pripraviti koristeći konvencionalne tehnike ili procese analogne onima prethodno opisanim u struci.
A main fuel composition for a compression ignition engine comprising at least 20% by weight methanol and 5-68% by weight water, and one or more additives selected from the group consisting of: ignition improvers, fuel extenders, combustion enhancers, oxygen absorbing oil, lubricity additives, product colouration additives, flame colour additives, anti corrosion additives, biocides, freeze point depressants, deposit reductants, denaturants, pH controlling agents, and mixtures thereof, wherein the composition comprises 0-20% by weight dimethyl ether. 
Uporaba pripravka za potpunu zamjenu dizelskog goriva za napajanje motora s kompresijskim paljenjem, pri čemu pripravak sadrži najmanje 20 tež. % metanola i od 3% do 40 tež. % vode, i jedan ili više aditiva odabranih iz skupine sastavljenih od: aditiva za poboljšanje paljenja, sredstva za povećanje goriva, sredstva za pojačavanje izgaranja, ulja za apsorpciju kisika, aditivi za podmazivanje, aditivi za bojanje proizvoda, aditivi za boju plamena, aditivi za zaštitu od korozije, biocida, sredstva za smrzavanje, sredstva za reduciranje taloženja, denaturirajuće tvari, sredstava za kontrolu pH i njihove smjese, pri čemu pripravak goriva ne sadrži dimetil eter ili sadrži dimetil eter u količini ne više od 20 tež. %.
In certain embodiments, the polymer G-CSF conjugate has the following formula: 
Vodeni pripravak koji sadrži polimer-G-CSF konjugat kao djelatnu tvar sa sljedećom formulom:
The pharmaceutical composition for use as claimed in Claim 8, which is for anti-osteoarthritis, anti-rheumatoid arthritis, or anti-gouty arthritis. 
Farmaceutski sastav za uporabu prema zahtjevu 8, naznačen time, da treba djelovati protiv osteoartritisa, protiv reumatoidnog artritisa ili protiv giht-artritisa.
MMVF according to claim 10 or 11, wherein the MMVF have a composition comprising the following oxides, expressed by wt of oxides: 
MMF sukladno patentnom zahtjevu 10 ili 11, naznačeno time da MMVEF ima spoj koji sadrži slijedeće okside, izraženo eksprimiranom težinom oksida:
providing a standardized core unit specifying hydrodynamic characteristics of the azimuth thruster, mounting hydrodynamic elements on the standardized core unit to meet the specified hydrodynamic characteristics. 
– osiguravanja standardizirane osnovne jedinice, – specificiranja hidrodinamičkih karakteristika zakretnog potisnika, – montiranja hidrodinamičkih elemenata na standardiziranu osnovnu jedinicu radi zadovoljavanja specificiranih hidrodinamičkih karakteristika.
The BS further includes a mapping module 703. The mapping module 703 is adapted to establish a corresponding relation between an uplink resource index and at least one uplink resource in terms of indication. 
BS prema zahtjevu 10, naznačena time da se nadalje sastoji od modula za mapiranje (703) koji je prilagođen za ostvarivanje odgovarajućeg odnosa između indeksa resursa za uzlaznu vezu i barem jednog resursa za uzlaznu vezu u smislu porijekla.
The method comprises: providing an oligosaccharide comprising a first reactive group, wherein the oligosaccharide is 
(a) osiguravanje oligosaharida koji sadrži prvi reaktivnu skupinu, pri čemu je oligosaharid "0gPQ HO o,
The crystalline salt form of Claim 8, wherein the crystalline salt form is characterized by an x-ray powder diffraction pattern in which the peak positions are substantially in accordance with the peak positions of the pattern shown in Figure 4. 
Kristalni oblik soli u skladu s patentnim zahtjevom 8, naznačen time, da je kristalni oblik soli karakteriziran rendgenskom difrakcijom u praškastom uzorku u kojem su vršne vrijednosti na položaju u bitnome u skladu s položajem vršnih vrijednosti uzorka prikazanog na Slici 4.
Lozenges according to the invention may comprise, for example, approximately 9-15% by weight water, preferably approximately 10-13% by weight water. 
Tablete prema izumu mogu sadržavati, na primjer, približno 9-15% vode po masi, poželjno približno 10-13% vode po masi.